Pfizer and Morgan State University Launch Vaccine Fellowship
Pfizer and Morgan State University’s program, a Doctor of Public Health (DrPH) Fellowship in Vaccines Medical Development, will officially begin on August 30th. The collaboration with Morgan State University is part of Pfizer’s continued partnership with Historically Black Colleges and Universities (HBCUs).
The two-year program aims to expand the number of minority scholar practitioners in the fields of medical development, as well as vaccine-related real-world data and analysis. The program will provide fellows the opportunity to:
- Contribute and lead in medical, clinical, and scientific affairs related to vaccines.
- Partner with key thought leaders, professional societies, and patient advocacy groups to identify areas of unmet medical need.
- Gain invaluable training and networking opportunities to pursue a successful career in the biopharmaceutical industry.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
